Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment

PharmacoEconomics
Gregorio BrevettiRoxanna Bucur

Abstract

The purpose of this article is to review the literature on the pharmacoeconomics of treatment for intermittent claudication and to discuss the importance of quality-of-life assessment for evaluating treatment strategies. Systemic risk reduction is the primary objective in the treatment of patients with intermittent claudication, as these patients have a high future risk of cardiovascular morbidity and mortality. Modification of cardiovascular risk factors accompanied by antiplatelet therapy is likely to improve overall survival, reduce myocardial infarction and stroke, and will, perhaps, also reduce the risk of ulcers and amputation at acceptable cost-effectiveness ratios. The second goal in the treatment of patients with intermittent claudication is to improve their walking capacity and community-based functional status. Supervised exercise training is the most effective noninvasive intervention to improve walking capacity, but may have elevated indirect costs. Among patients with disabling claudication who are candidates for invasive therapeutic procedures, angioplasty is cost effective in those with femoropopliteal stenosis or occlusion and in those with critical limb ischaemia and a stenosis. For all these therapeutic strat...Continue Reading

References

Mar 1, 1977·British Journal of Preventive & Social Medicine·G RoseD D Reid
Jun 1, 1992·Archives of Internal Medicine·A StergachisD A Revicki
Feb 6, 1992·The New England Journal of Medicine·M H CriquiD Browner
Aug 22, 1991·The New England Journal of Medicine·J D Coffman
Aug 22, 1991·The New England Journal of Medicine·S R TunisE P Steinberg
Jul 1, 1991·The British Journal of Surgery·D S O'Riordain, J A O'Donnell
Apr 25, 1991·The New England Journal of Medicine·R ClarkeI Graham
Jul 15, 1990·Annals of Internal Medicine·K Radack, R J Wyderski
Oct 1, 1990·Circulation·S Furman
Jul 1, 1989·Annals of Vascular Surgery·M D McDaniel, J L Cronenwett
Oct 1, 1988·European Journal of Vascular Surgery·F G Fowkes
Jan 1, 1985·American Journal of Epidemiology·J F SallisR S Paffenbarger
Jan 12, 1984·The New England Journal of Medicine·P Doubilet, H L Abrams
Oct 1, 1995·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·I C CurrieP M Lamont
Nov 15, 1995·Journal of the American College of Cardiology·G BrevettiM Condorelli
Jul 1, 1995·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·D BergqvistJ P Dickinson
Sep 1, 1994·American Journal of Epidemiology·S J BowlinU Goldbourt
Nov 15, 1993·Journal of the American College of Cardiology·H M KrumholzM C Weinstein
Nov 1, 1993·European Journal of Clinical Investigation·B ArfvidssonM Sullivan
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 1, 1996·Journal of Vascular Surgery·J G RegensteinerW R Hiatt
Aug 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M R WhymanC V Ruckley
May 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·I SmithJ T Powell
May 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·J M PerkinsP J Morris

❮ Previous
Next ❯

Citations

Jun 1, 2005·Journal of the American College of Surgeons·Roderick T ChewAchilleas Thoma
Feb 22, 2003·Journal of the American College of Surgeons·William H Pearce
Jun 30, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Anna Maria MalagoniFabio Manfredini
Mar 23, 2010·PharmacoEconomics·Mattias Neyt
Aug 15, 2003·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K CassarJ Brittenden
Jun 30, 2009·Annals of the Royal College of Surgeons of England·Joseph ShalhoubAlun H Davies
Dec 6, 2005·Drugs & Aging·David R Goldsmith, Keri Wellington
Dec 8, 2009·British Journal of Hospital Medicine·Alexander J HillsAlun H Davies
May 12, 2009·Vascular·Joseph ShalhoubAlun Davies

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Yusuke NakagawaHiroaki Matsubara
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
M J SmithAlan R Scott
Clinical Cardiology
J W HaS Y Cho
© 2022 Meta ULC. All rights reserved